Dominican Partners with Biotech Firm for Project

The collaborative project, funded with a STTR (Small Business Technology Transfer) grant from the National Institutes of Health (NIH), involves preclinical stage II development of a new chloroquine analog, called a Reversed Chloroquine Compound (RCQ), a class of molecules effective against multi-drug resistant forms of human malarias. The Dominican research team, led by Dr. Roland Cooper, will evaluate the molecules supplied by DesignMedix for efficacy against a variety of chloroquine-resistant strains of malari